7 Powerful Advances in the ASCO 2026 Guideline for Driver
The ASCO 2026 guideline for metastatic non-small-cell lung cancer emphasizes the necessity of broad multigene profiling for treatment decisions. It highlights that precision oncology now requires identifying specific driver mutations rather than relying solely on histology or PD-L1 expression.
Why it matters
This guideline represents a significant shift in clinical practice, potentially improving survival rates by ensuring patients receive targeted therapies based on molecular diagnostics.
The era in which metastatic non-small-cell lung cancer was treated primarily according to histology is increasingly distant.
For many patients today, the first treatment decision is determined not simply by whether the tumor is adenocarcinoma or squamous carcinoma, nor by PD-L1 expression alone, but by a molecular question: What is driving this cancer?
The ASCO Living Guideline Version 2026.3.3 for stage IV NSCLC with driver alterations captures how far this concept has evolved.
The guideline spans EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2, KRAS G12C and NRG1-driven disease and addresses both first-line and subsequent therapy. But its most important message is broader than a list of targeted drugs. Precision oncology in NSCLC has entered a second generation.
Finding the driver is only the beginning.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in